TY  - JOUR
AU  - Morales-Cano, Daniel
AU  - Barreira, Bianca
AU  - Pandolfi, Rachele
AU  - Villa-Valverde, Palmira
AU  - Izquierdo García, José Luis
AU  - Esquivel Ruiz, Sergio Antonio
AU  - Callejo Arranz, María
AU  - Rodríguez Ramírez De Arellano, Ignacio
AU  - Cogolludo Torralba, Ángel Luis
AU  - Ruiz-Cabello Osuna, Jesús
AU  - Pérez Vizcaíno, Francisco
AU  - Moreno Gutiérrez, Laura
PY  - 2023
DO  - 10.3389/fphar.2023.1021535
UR  - https://hdl.handle.net/20.500.14352/92876
T2  - Front. Pharmacol
AB  - Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH...
LA  - eng
PB  - Frontiers
KW  - Pulmonary hypertension,
KW  - Antiproliferative
KW  - Metabolomics
KW  - Combination therapy
KW  - Right ventricle
TI  - Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model
TY  - journal article
VL  - 14
ER  -